Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 12/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497449 | 0.82 | DPP4 (0.50) | DPP4SMN1; SMN2KMT2ALMNARAB9A | |
| SCHEMBL20248001 | 0.81 | DPP4 (0.85) | DPP4 | |
| SCHEMBL20041946 | 0.80 | DPP4 (1.00) | DPP4 | |
| SCHEMBL20041939 | 0.80 | DPP4 (1.00) | DPP4 | |
| SCHEMBL26661309 | 0.80 | DPP4 (0.67) | DPP4SMN1; SMN2MEN1CYP2C9CYP2C19 | |
| SCHEMBL638215 | 0.79 | DPP4 (0.55) | DPP4SMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL638365 | 0.78 | DPP4 (0.46) | DPP4SMN1; SMN2MEN1CYP2C9CYP2C19 | |
| SCHEMBL20041950 | 0.77 | DPP4 (0.63) | DPP4SMN1; SMN2LMNAKDM4ERAB9A | |
| SCHEMBL637295 | 0.76 | SMN1; SMN2 (0.53) | DPP4SMN1; SMN2MEN1CYP2C9CYP2C19 | |
| SCHEMBL3917633 | 0.76 | DPP4 (0.54) | DPP4SMN1; SMN2CYP2C9CYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3305787-B1 | XANTHINE DERIVATIVE | JIANGSU TASLY DIYI PHARMACEUTICAL CO LTD (CN) | 2022-02-16 | — | — | EP | disclosed |
| US-20180162860-A1 | XANTHINE DERIVATIVE | JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD. (CN) | 2018-06-14 | — | — | US | disclosed |
| EP-3305787-A1 | XANTHINE DERIVATIVE | Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (CN) | 2018-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162860-A1 | XANTHINE DERIVATIVE | XDH, CXCR1, CBR1 | DPP4 1294/4885SMN1; SMN2 2841/4885MEN1 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.